Production of Therapeutic (casirivimab and imdevimab) in Support of National Emergency Response to Coronavirus 2019 (COVID-19)

Award Notice Posted

Solicitation number
W15QKN-21-C-0014
Agency
Awarded
to Regeneron Pharmaceuticals Inc.
Set-aside
No set-aside

Opportunity facts

Contract number
W15QKN-21-C-0014 Federal contract award

Notice details come from SAM.gov. Updated .

About this opportunity

Written by GovTribe AI ·

The Department of the Army Materiel Command Contracting Command Picatinny Arsenal awarded a sole source contract to Regeneron Pharmaceuticals, Inc. for the production of the Regeneron therapeutic casirivimab and imdevimab in support of the national emergency response to COVID-19. The contract, awarded under the authority of 10 U.S.C. 2304(c)(2) and FAR 6.302-2 for unusual and compelling urgency, has a value of $2,625,000,000 and will support the production of the therapeutic to aid in combating the effects of the COVID-19 pandemic.

Notice text

Production of Regeneron Therapeutic (casirivimab and imdevimab) in Support of National Emergency Response to Coronavirus 2019 (COVID-19). This is a sole source action under the authority of 10 United States Code (U.S.C.) 2304(c)(2), as implemented by Federal Acquisition Regulation (FAR) 6.302-2 -- Unusual and Compelling Urgency.

Awarded contract W15QKN-21-C-0014 to REGENERON PHARMACEUTICALS, INC. for 2625000000.00 on 2021-01-12.

Notice history

Notice Type Posted
Production of an Additional 1. 4M Doses of REGEN-COV Latest Award Notice
Posting of J&A - Production of Therapeutic (casirivimab and imdevimab) in Support of National Emergency Response to Coronavirus 2019 (COVID-19) Limited / Sole Source Justification
This notice Original Award Notice

On GovTribe

Work this opportunity

  • Track it in your pipeline
  • Find teaming partners
  • Similar opportunities
  • Ask GovTribe AI about this opportunity
Try for free Login

GovTribe for Federal Contractors